More on AINMF
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $0.64 |
|
|||
| Open | $0.60 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $0.61 | ||||
| Day Low | $0.59 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 26,000 | ||||
- NetraMark to Present at the American Society of Clinical Psychopharmacology Annual Meeting
- NetraMark Provides Second Quarter Update and Highlights Continued Commercial, Scientific, Regulatory and Capital Markets Momentum
- NetraMark director Lawrence Guy resigns from board
- NetraMark Announces Change To Board Of Directors
- NetraMark names Dr. Panteli Theocharous fractional chief medical officer
- NetraMark Appoints Dr. Panteli Theocharous As Fractional Chief Medical Officer, Strengthening Clinical Leadership To Accelerate Global Adoption of NetraAI
- NetraMark To Open The Market At The Toronto Stock Exchange On May 5, 2026
- NetraMark Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs
- Netramark Comments on U.S. Executive Order to Accelerate Treatments for Serious Mental Illness and Highlights the Need for Regulatory‑Grade Trial Design in Psychedelic Development
- Netramark-Authored, Peer-Reviewed Article Suggests Psychedelics Might Not Only Affect Brain Chemistry, They May Also Involve Quantum-Level Processes Inside the Brain
